Blocking IL-1 to prevent respiratory failure in COVID-19.
Crit Care
; 24(1): 445, 2020 07 18.
Article
in English
| MEDLINE | ID: covidwho-655347
ABSTRACT
COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the pathogenesis of severe infections and ARDS and evidence is emerging that the IL-1/IL-6 pathway is highly upregulated in patients with severe disease. These findings open new avenues for host-directed therapies in patients with symptomatic SARS-CoV-2 infection and might in addition to antiviral treatment be enough to curb the currently unacceptably high morbidity and mortality associated with COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Respiratory Insufficiency
/
Interleukin-1
/
Coronavirus Infections
Topics:
Long Covid
/
Variants
Limits:
Humans
Language:
English
Journal:
Crit Care
Year:
2020
Document Type:
Article
Affiliation country:
S13054-020-03166-0
Similar
MEDLINE
...
LILACS
LIS